ERIC SPEARE: Open Payments
NPI 1306984570 · DANA POINT, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$950 in 45 payments from 12 companies in 2025. Trend: 2023 $1,085 · 2024 $528 · 2025 $950
Food & beverage: $950
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 10 | $173 |
| Otsuka America Pharmaceutical, Inc. | 8 | $154 |
| Alkermes, Inc. | 7 | $141 |
| E.R. Squibb & Sons, L.L.C. | 3 | $86 |
| Vanda Pharmaceuticals Inc. | 4 | $86 |
| Janssen Pharmaceuticals, Inc | 3 | $71 |
| Lundbeck LLC | 3 | $68 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $52 |
| Supernus Pharmaceuticals, Inc. | 2 | $43 |
| Axsome Therapeutics, Inc. | 1 | $32 |
Products named: REXULTI, VRAYLAR, ARISTADA, COBENFY, SPRAVATO, FANAPT, CAPLYTA, ABILIFY ASIMTUFII.
Industry payments across CA — which companies pay providers there.
